Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

被引：0
|
作者：
A. Hemeryck
C. De Vriendt
F. M. Belpaire
机构：
[1] Heymans Institute of Pharmacology,
[2] University of Gent Medical School,undefined
[3] 9000 Gent,undefined
[4] Belgium e-mail: frans.belpaire@rug.ac.be Tel.: +32-9-2403355; Fax: +32-9-2404988,undefined
来源：
European Journal of Clinical Pharmacology | 1999年 / 54卷
关键词：
Key words CYP2C9; SSRI; (S)-warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To investigate the in vitro potential of selective serotonin reuptake inhibitors (SSRIs) to inhibit two CYP2C9-catalysed reactions, tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.
引用
收藏
页码：947 / 951
页数：4
相关论文
共 50 条
  • [21] Thymoquinone Increased Warfarin 7-hydroxylation in Human Liver Microsomes and Induced the Expression of CYP2C9 in HepG2 Cells
    Megawati, Annik
    Nugroho, Agung Endro
    Lukitaningsih, Endang
    Prihati, Dita Amalia
    Nurrochmad, Arief
    INDONESIAN JOURNAL OF PHARMACY, 2024, 35 (04): : 629 - 640
  • [22] Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes
    Li Zhang
    Min-ji Wei
    Cai-yun Zhao
    Hui-min Qi
    Acta Pharmacologica Sinica, 2008, 29 : 1507 - 1514
  • [23] Inhibitory effects of angiotensin receptor Blockers on CYP2C9 activity in human liver Microsomes
    Kamiyama, Emi
    Yoshigae, Yasushi
    Kasuya, Atsushi
    Takei, Makoto
    Kurihara, Atsushi
    Ikeda, Toshihiko
    DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (04) : 267 - 275
  • [24] Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes
    Zhang, Li
    Wei, Min-ji
    Zhao, Cai-yun
    Qi, Hui-min
    ACTA PHARMACOLOGICA SINICA, 2008, 29 (12) : 1507 - 1514
  • [25] Effects of CYP2C9*3,*28 and*30 on CYP2C9 inhibition profiles and glyburide metabolism in vitro
    Maekawa, Keiko
    Harakawa, Noriko
    Kim, Su-Ryang
    Sawada, Jun-ichi
    Saito, Yoshiro
    DRUG METABOLISM REVIEWS, 2011, 43 : 61 - 61
  • [26] CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
    Wester, MR
    Lasker, JM
    Johnson, EF
    Raucy, JL
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (03) : 354 - 359
  • [27] Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes
    Miyazawa, M
    Shindo, M
    Shimada, T
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) : 602 - 607
  • [28] Development of an In Vitro System with Human Liver Microsomes for Phenotyping of CYP2C9 Genetic Polymorphisms with a Mechanism-Based Inactivator
    Flora, Darcy R.
    Tracy, Timothy S.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 836 - 842
  • [29] Characterization of CYP2C19 and CYP2C9 from human liver:: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
    Lasker, JM
    Wester, MR
    Aramsombatdee, E
    Raucy, JL
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 353 (01) : 16 - 28
  • [30] Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies
    Prasad, G. Shyam
    Srisailam, K.
    Sashidhar, R. B.
    SPRINGERPLUS, 2016, 5 : 1 - 9
12345